title: Evaluation of different perfusion durations in direct hemoperfusion with polymyxin B-immobilized fiber column therapy for acute exacerbation of interstitial pneumonias.
abstract: BACKGROUND
  Recently, the potential therapeutic effect of direct hemoperfusion with a polymyxin B-immobilized fiber column (PMX-DHP) has been reported for acute exacerbation of interstitial pneumonia (AE-IP), a highly morbid clinical event; however, there is no consensus on the appropriate procedure for PMX-DHP. We examined the appropriate perfusion duration of PMX-DHP for AE-IP.
  
  
  METHODS
  AE-IP patients receiving PMX-DHP were divided into two groups: short-duration group (≤6 h) (n = 5) and long-duration group (12 h) (n = 12).
  
  
  RESULTS
  ThePaO(2)/FiO(2) (P/F) ratio increased immediately after PMX-DHP in the two groups. In the long-duration group, the P/F ratio continued to increase over the following 7 days, while, in the short-duration group, the P/F ratio declined again 3 days after therapy. The survival rate 30 days after PMX-DHP was significantly higher in the long-duration group than in the short-duration group.
  
  
  CONCLUSIONS
  A long perfusion duration of PMX-DHP is more efficacious for AE-IP than a short perfusion duration.
authors.affiliation: Second Division, Department of Internal Medicine, Hamamatsu, Japan.
authors.forename: Masato
authors.initials: M
authors.lastname: Kono
authors.forename: Takafumi
authors.initials: T
authors.lastname: Suda
authors.forename: Noriyuki
authors.initials: N
authors.lastname: Enomoto
authors.forename: Yutaro
authors.initials: Y
authors.lastname: Nakamura
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kaida
authors.forename: Dai
authors.initials: D
authors.lastname: Hashimoto
authors.forename: Naoki
authors.initials: N
authors.lastname: Inui
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Mizuguchi
authors.forename: Akihiko
authors.initials: A
authors.lastname: Kato
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Shirai
authors.forename: Hirotoshi
authors.initials: H
authors.lastname: Nakamura
authors.forename: Kingo
authors.initials: K
authors.lastname: Chida
mesh_terms: D000208:Acute Disease; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003997:Dicarbethoxydihydrocollidine / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism; D005260:Female; D006464:Hemoperfusion / Q000379:methods*; D006801:Humans; D055767:Immobilized Proteins / Q000737:chemistry / Q000378:metabolism*; D017563:Lung Diseases, Interstitial / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D011112:Polymyxin B / Q000737:chemistry / Q000378:metabolism* / Q000627:therapeutic use; D012129:Respiratory Function Tests; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C105562:2,6-dimethyl-3,5-diethoxycarbonyl-4-carboxyl-1,4-dihydropyridine; D000305:Adrenal Cortex Hormones; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D055767:Immobilized Proteins; D003997:Dicarbethoxydihydrocollidine; D011112:Polymyxin B